Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Thymocyte selection-associated high mobility group box protein (TOX) mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the TOX transcript, which encodes a key transcription factor driving T cell exhaustion (Khan et al., Nature 2019, https://doi.org/10.1038/s41586-019-1329-0). In the context of chronic antigen exposure, such as in cancer or chronic viral infections, TOX expression is sustained, leading to the epigenetic remodeling of T cells into an exhausted state characterized by high inhibitory receptor expression and reduced effector function (Alfei et al., Nature 2019, https://doi.org/10.1038/s41586-019-1312-9). The 3'UTR contains specific sequences that serve as binding sites for microRNAs, such as miR-181a-5p, which have been shown to regulate TOX levels and influence T cell persistence (Li et al., Cell Reports 2022, https://doi.org/10.1016/j.celrep.2022.111052). These regulatory interactions dictate the half-life and translational efficiency of the TOX message, making the 3'UTR a focal point for post-transcriptional control. Therapeutic targeting of this region via antisense oligonucleotides (ASOs) or miRNA mimics aims to downregulate TOX levels, thereby preventing or reversing T cell exhaustion. This approach is designed to enhance the anti-tumor immune response by maintaining the functionality of tumor-infiltrating lymphocytes. Furthermore, modulating the TOX mRNA 3'UTR is being explored as a method to improve the efficacy of CAR-T cell therapies and immune checkpoint inhibitors. Challenges include ensuring the specificity of RNA-targeting agents and achieving efficient delivery to the relevant immune cell populations within the tumor microenvironment.
Reduction of TOX protein expression through antisense-mediated mRNA degradation or microRNA-induced translational repression and mRNA decay.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thymocyte selection-associated high mobility group box protein mRNA 3' untranslated region (TOX mRNA 3'UTR).